These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

727 related articles for article (PubMed ID: 15254063)

  • 1. The biology and clinical relevance of the PTEN tumor suppressor pathway.
    Sansal I; Sellers WR
    J Clin Oncol; 2004 Jul; 22(14):2954-63. PubMed ID: 15254063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
    Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
    Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.
    Weng LP; Smith WM; Dahia PL; Ziebold U; Gil E; Lees JA; Eng C
    Cancer Res; 1999 Nov; 59(22):5808-14. PubMed ID: 10582703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pten signaling in gliomas.
    Knobbe CB; Merlo A; Reifenberger G
    Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
    Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
    Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
    Zhang J; Choi Y; Mavromatis B; Lichtenstein A; Li W
    Oncogene; 2003 Sep; 22(40):6289-95. PubMed ID: 13679867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.
    Xu G; Zhang W; Bertram P; Zheng XF; McLeod H
    Int J Oncol; 2004 Apr; 24(4):893-900. PubMed ID: 15010827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.
    Podsypanina K; Lee RT; Politis C; Hennessy I; Crane A; Puc J; Neshat M; Wang H; Yang L; Gibbons J; Frost P; Dreisbach V; Blenis J; Gaciong Z; Fisher P; Sawyers C; Hedrick-Ellenson L; Parsons R
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10320-5. PubMed ID: 11504907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells.
    Van de Sande T; De Schrijver E; Heyns W; Verhoeven G; Swinnen JV
    Cancer Res; 2002 Feb; 62(3):642-6. PubMed ID: 11830512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
    Ramaswamy S; Nakamura N; Vazquez F; Batt DB; Perera S; Roberts TM; Sellers WR
    Proc Natl Acad Sci U S A; 1999 Mar; 96(5):2110-5. PubMed ID: 10051603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
    Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
    Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
    Neshat MS; Mellinghoff IK; Tran C; Stiles B; Thomas G; Petersen R; Frost P; Gibbons JJ; Wu H; Sawyers CL
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10314-9. PubMed ID: 11504908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention.
    Steelman LS; Bertrand FE; McCubrey JA
    Expert Opin Ther Targets; 2004 Dec; 8(6):537-50. PubMed ID: 15584861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
    Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
    Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN: life as a tumor suppressor.
    Simpson L; Parsons R
    Exp Cell Res; 2001 Mar; 264(1):29-41. PubMed ID: 11237521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN and myotubularin: novel phosphoinositide phosphatases.
    Maehama T; Taylor GS; Dixon JE
    Annu Rev Biochem; 2001; 70():247-79. PubMed ID: 11395408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells.
    Kandasamy K; Srivastava RK
    Cancer Res; 2002 Sep; 62(17):4929-37. PubMed ID: 12208743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo.
    Kwon CH; Zhu X; Zhang J; Baker SJ
    Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12923-8. PubMed ID: 14534328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
    She QB; Solit D; Basso A; Moasser MM
    Clin Cancer Res; 2003 Oct; 9(12):4340-6. PubMed ID: 14555504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.